Under the agreement, J&J will acquire Shockwave for $335.00 per share in cash, which represents approximately $13.1 billion. Both companies’ board of directors have approved the transaction.
The acquisition will expand J&J’s reach in the heart device market. The company acquired Abiomed in 2022 for $16.6 billion and Laminar in late 2023 for $400 million, according to The Wall Street Journal.
The deal is expected to close by mid-2024.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.